Catalyst Acquires Late-Stage Orphan Drug From BioMarin

BioMarin Pharmaceutical has licensed North American rights to its EC-approved orphan drug Firdapse (amifampridine phosphate) to Catalyst Pharmaceutical Partners, and is making a $5 million investment in Catalyst to support the latter’s development of the drug in the U.S.
Genetic Engineering & Biotechnology News